ルニットのAIがん検出プラットフォーム、肺および乳がんスクリーニングでFDA承認を取得
Lunit's FDA clearance validates the global competitiveness of Korean AI medtech and could accelerate the adoption of AI-assisted cancer screening across APAC's healthcare systems.
Lunit secured FDA 510(k) clearance for its AI lung and breast cancer detection platforms, enabling market entry into the United States.
韩国 AI 医学影像公司 Lunit 获得 FDA 510(k) 许可，用于肺结节和乳腺癌检测。
Lunit's FDA clearance validates the global competitiveness of Korean AI medtech and could accelerate the adoption of AI-assisted cancer screening across APAC's healthcare systems.
Where this signal fits in the broader landscape.
https://www.lunit.io/en/media-hub/lunits-ai-software-for-breast-cancer-detection-lunit-insight-mmg-wins-fda-clearance/
Read Full SourceGet curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
Sign in to save notes on signals.
ログイン